Abstract: A unit dosage form comprising atorvastatin or a pharmaceutically acceptable salt thereof, prepared without a granulation step, wherein the measured atorvastatin potency of said dosage form shows a relative standard deviation (RSD) for atorvastatin potency per unit dosage form of not more than about 7.8%, when said unit dosage form is prepared at a rate that greater than 10,000 unit dosage forms per hour per single unit dosage form per machine, as well as the unit dosage form in combination with at least one active drug, methods for preparing unit dosage form, kits for containing such compositions and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's Disease using a therapeutically effective amount of the unit dosage form.

Abstract: A dosage form that includes a cholesteryl ester transfer protein inhibitor in a solubility-improved form and an HMG-CoA reductase inhibitor, wherein the dosage form provides immediate release of the HMG-CoA reductase inhibitor and controlled release and immediate release of the cholesteryl ester transfer protein inhibitor.

Abstract: A unit dosage form comprising atorvastatin or a pharmaceutically acceptable salt thereof, prepared without a granulation step, wherein the measured atorvastatin potency of said dosage form shows a relative standard deviation (RSD) for atorvastatin potency per unit dosage form of not more than about 7.8%, when said unit dosage form is prepared at a rate that greater than 10,000 unit dosage forms per hour per single unit dosage form per machine, as well as the unit dsoage form in combination with at least one active drug, methods for preparing unit dosage form, kits for containing such compositions and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's Disease using a therapeutically effective amount of the unit dosage form.

Abstract: The present invention provides controlled-release pharmaceutical formulations comprising phosphodiesterase type 4D (PDE4D) inhibitors having improved release profiles to an environment of use.

Abstract: The invention provides controlled release pharmaceutical formulations having a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying essentially separate regions within the core. The drug-containing composition comprises a PDE4D inhibitor, or a pharmaceutically acceptable salt thereof, preferably (R)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid, or a pharmaceutically acceptable salt thereof, or 2-(4-fluorophenoxy)-N-[4-(1-hydroxy-1-methyl-ethyl)-benzyl]-nicotinamide, or a pharmaceutically acceptable salt thereof, and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble, and has at least one delivery port therethrough.